Intermittent Administration of Tacrolimus Enhances Anti-Tumor Immunity in Melanoma-Bearing Mice

Scientists indicated that intermittently blocking TCR signal by tacrolimus could promote anti-tumor immunity and inhibit the tumor growth in melanoma-bearing mice, inhibiting the transcription of several exhaustion-related genes, such as Nr4a1 and Ctla4.